Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $425.49M | $305.96M | $263.84M | $142.34M | $107.42M | $92.82M | $104.44M | $93.43M |
| Cost of revenue | $67.21M | $47.42M | $44.22M | $29.37M | $28.08M | $21.28M | $26.15M | $21.17M |
| Gross profit | $358.27M | $258.54M | $219.62M | $112.98M | $79.34M | $71.55M | $78.29M | $72.26M |
| Gross margin | 84.2% | 84.5% | 83.2% | 79.4% | 73.9% | 77.1% | 75.0% | 77.3% |
| Research and development | $210.03M | $209.49M | $254.91M | $186.42M | $177.19M | $152.58M | $179.73M | $150.81M |
| Selling, general and administrative | $247.47M | $247.26M | $212.48M | $186.38M | $154.76M | $147.55M | $142.52M | $118.93M |
| Operating expenses | $359.82M | $411.86M | $539.37M | $478.98M | $392.22M | $319.69M | $308.71M | $285.68M |
| Operating income | −$1.55M | −$153.32M | −$319.75M | −$366.01M | −$312.88M | −$248.14M | −$230.41M | −$213.43M |
| Operating margin | -0.4% | -50.1% | -121.2% | -257.1% | -291.3% | -267.3% | -220.6% | -228.4% |
| EBITDA | $3.71M | −$148.31M | −$314.19M | −$362.01M | −$309.13M | −$244.99M | −$227.67M | −$210.71M |
| Interest income | $10.98M | $12.04M | $15.24M | $18.29M | $13.23M | $13.91M | $17.26M | $16.98M |
| Interest expense | −$20.27M | −$20.08M | −$20.60M | −$20.38M | −$21.25M | −$21.57M | −$21.55M | −$21.05M |
| Income before taxes | −$11.37M | −$162.10M | −$326.93M | −$368.70M | −$320.44M | −$255.67M | −$234.28M | −$219.51M |
| Income taxes | $1.87M | $1.47M | $1.55M | $1.32M | $1.24M | $912.00K | $1.27M | $1.01M |
| Net income | −$13.24M | −$163.56M | −$328.49M | −$370.02M | −$321.69M | −$256.58M | −$235.55M | −$220.52M |
| Net margin | -3.1% | -53.5% | -124.5% | -260.0% | -299.5% | -276.4% | -225.5% | -236.0% |
| EPS, basic | −$0.06 | −$0.76 | −$1.53 | −$1.75 | −$1.70 | −$1.42 | −$1.31 | −$1.27 |
| EPS, diluted | −$0.06 | −$0.76 | −$1.53 | −$1.75 | −$1.70 | −$1.42 | −$1.31 | −$1.27 |
| Diluted shares | 217.35M | 215.47M | 214.14M | 211.76M | 189.30M | 180.86M | 179.29M | 173.72M |
Figures describe Insmed shares, not any token. As of Aug 6, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.